Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 2Neoplasms 2Melanoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Skin Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasm Metastasis 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Hairy Cell 1Leukemia 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hepatoblastoma 1Glioma 1Ependymoma 1Craniopharyngioma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

selpercatinib 3trametinib 2entrectinib 2cabozantinib 2Magnetic Resonance Spectroscopy 2spartalizumab 1omipalisib 1dabrafenib 1Vemurafenib 1Specimen Handling 1Sodium Iodide 1Postoperative Period 1Nivolumab 1Ipilimumab 1Iodine-131 1Iodine-124 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Cancer, Papillary × Vemurafenib × Clear all
NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
24 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡